C-Met is a tyrosine kinase receptor that is encoded in part by a mesenchymal-epidermal transition (MET) exon 14. Mutations in the MET gene can lead to increased c-MET signalling and oncogenic stimulation. Although c-MET mutation is rare, it is a targetable driver mutation.
Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Epidemiological Segmentation
The Epidemiological Segmentation of Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) in 7MM from 2017 to 2030 is segmented as:-
- Total Incident Cases of NSCLC patients
- Total Incident Cases of NSCLC Patients by Histology
- Total Diagnosed Cases of NSCLC Patients by Stages
- Total Incident Cases of C-Met NSCLC
- Treated Patient Pool of C-Met NSCLC
Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Epidemiology
- Total incident cases of C-Met mutated NSCLC in 7MM in 2017 were 16,658C-Met accounted for around 4% of the total cases of NSCLC
- The total cases of C-Met mutated NSCLC in the United States were 7,202 in 2017
The market size of C-Met mutated NSCLC in 7MM in 2017 was USD 186 million.
Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Market Drivers
- Increasing Use of Biomarker Testing
- Increase in the Mutation Specific Trials Activity
- Increasing Incidence of C-Met mutated NSCLC
Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Market Barriers
- Cost-Effectiveness of Therapies
- Small Patient Populations of C-Met mutated NSCLC
- Cost of Therapies
- Burden of Disease
Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Emerging Drugs
The emerging drugs of the Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) market are
- Tepmetko (tepotinib)
- Merestinib
- Telisotuzumab Vedotin
- JNJ-61186372 (JNJ-6372)
- Canakinumab (ACZ885)
- Cabozantinib
- Sym015
And many others.
Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Key Players
The key players in the Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) market are
- Novartis Pharmaceuticals
- Merck KGaA
- Eli Lilly and Company
- AbbVie
- Janssen Research & Development
- Exelixis
- Ipsen
- Takeda
- Symphogen
And many others.